HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
Erkki LathouwersEric Y WongDonghan LuoSareh SeyedkazemiSandra De MeyerKimberley BrownPublished in: HIV clinical trials (2017)
Darunavir has a high genetic barrier to resistance. Across a diverse population of HIV-1-infected subjects treated with darunavir 800 mg QD regimens, the development of darunavir resistance was rare (<0.1%).
Keyphrases
- hiv infected
- hiv infected patients
- antiretroviral therapy
- end stage renal disease
- human immunodeficiency virus
- newly diagnosed
- hiv positive
- hiv aids
- ejection fraction
- chronic kidney disease
- hepatitis c virus
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- dna methylation
- copy number
- south africa
- gene expression
- men who have sex with men